MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

12 Aug 2026 Evaluate
Revenue showed a marginal decline at Rs. 163.89 millions. For the quarter ended June 2026, as compared to corresponding quarter of last year.Profit for the quarter ended June 2026 increased merely by2.24% to Rs. 2.28  millions from Rs. 2.23 millions.OP of the company witnessed a marginal growth to 5.55 millions from 5.42 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 163.89 166.99 -1.86 163.89 166.99 -1.86 699.34 671.92 4.08
Other Income 0.17 0.18 -5.56 0.17 0.18 -5.56 4.44 1.68 164.29
PBIDT 5.55 5.42 2.40 5.55 5.42 2.40 34.43 29.30 17.51
Interest 0.30 0.26 15.38 0.30 0.26 15.38 1.12 1.03 8.74
PBDT 5.25 5.16 1.74 5.25 5.16 1.74 33.31 28.27 17.83
Depreciation 1.64 1.78 -7.87 1.64 1.78 -7.87 6.77 6.71 0.89
PBT 3.61 3.38 6.80 3.61 3.38 6.80 26.54 21.56 23.10
TAX 1.33 1.15 15.65 1.33 1.15 15.65 8.89 6.07 46.46
Deferred Tax 0.39 0.06 550.00 0.39 0.06 550.00 1.04 0.18 477.78
PAT 2.28 2.23 2.24 2.28 2.23 2.24 17.65 15.49 13.94
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 96.61 0.00
PBIDTM(%) 3.39 3.25 4.33 3.39 3.25 4.33 4.92 4.36 12.90
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..